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The nuclear factor-κB (NF-κB) family of transcription
factors is essential for the expression of pro-inflammatory
cytokines, but can also induce regulatory pathways.
NF-κB can be activated via two distinct pathways: the
classical or canonical pathway, and the alternative or
non-canonical pathway. It is well established that the
canonical NF-κB pathway is essential both in acute
inflammatory responses and in chronic inflammatory
diseases, including rheumatoid arthritis (RA). Although
less extensively studied, the non-canonical NF-κB
pathway is not only central in lymphoid organ
development and adaptive immune responses, but
is also thought to play an important role in the
pathogenesis of RA. Importantly, this pathway appears
to have cell type-specific functions and, since many
different cell types are involved in the pathogenesis of
RA, it is difficult to predict the net overall contribution
of the non-canonical NF-κB pathway to synovial
inflammation. In this review, we describe the current
understanding of non-canonical NF-κB signaling in
various important cell types in the context of RA and
consider the relevance to the pathogenesis of the
disease. In addition, we discuss current drugs targeting
this pathway, as well as future therapeutic prospects.The most extensively studied NF-κB activation pathway
is the canonical pathway (Figure 1), which can be acti-Introduction
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a disabling chronic inflam-
matory autoimmune disease affecting the synovial joints.
In the early phase of the disease, the synovial tissue is
infiltrated by immune cells and increases in thickness,
which causes pain, stiffness and swelling of the joint. The* Correspondence: S.W.Tas@amc.uva.nl
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cells, macrophages, and other cells. These cells contribute
to the inflammatory process via the production of matrix
metalloproteinases (MMPs), cytokines and chemokines,
followed by the influx and activation of more immune cells
into the synovial tissue. From the earliest stage of the dis-
ease, neoangiogenesis can be observed, which contributes
to chronicity. Eventually, the loss of articular cartilage,
along with damage to the joint capsule and peri-articular
structures, causes deformities (reviewed in [1]).
In RA synovial tissue many signal transduction pathways
are activated [2]. One of the most important signaling
pathways involved in the pathogenesis of RA is the nuclear
factor-κB (NF-κB) pathway (reviewed in [3]).Nuclear factor-κB
NF-κB is expressed ubiquitously in the cytoplasm of almost
all cell types. Many diseases, including cancer, and inflam-
matory and autoimmune diseases, are associated with
dysregulation of NF-κB (reviewed in [4]). NF-κB can be ac-
tivated via two distinct pathways, the classical or canonical
NF-κB pathway, and the alternative or non-canonical
NF-κB pathway.The canonical NF-κB pathway
vated by stimulation of a variety of cell membrane recep-
tors, including tumor necrosis factor (TNF) receptor,
interleukin (IL)-1 receptor, and Toll-like receptors, in re-
sponse to pro-inflammatory stimuli like lipopolysaccha-
ride, IL-1 and TNF, as well as via triggering of the T-cell
receptor or B-cell receptor. In this pathway, inhibitor of
κB kinase (IKK)β is required for NF-κB activation, whereas
IKKα is redundant [4]. The canonical NF-κB pathway is
essential both in acute inflammatory responses and in
chronic inflammatory diseases such as RA and inflamma-
tory bowel disease. Moreover, this pathway is important in
cell proliferation and survival, demonstrated by constitu-
tively active NF-κB signaling in many tumor tissues [5]. Inhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Overview of nuclear factor-κB activation pathways. Schematic representation of the canonical and non-canonical nuclear factor
(NF)-κB pathways. The canonical NF-κB pathway can be activated by a variety of different stimuli, like tumor necrosis factor-α and lipopolysaccharide
(LPS). Activation of the canonical pathway via Toll-like receptor or cytokine receptor signaling depends on the inhibitor of κB kinase (IKK) complex,
which is composed of the kinases IKKα and IKKβ, and the regulatory subunit IKKγ (NEMO). Activated IKK phosphorylates the inhibitory subunit
IκBα to induce its degradation, allowing NF-κB dimers (p50-p65) to translocate to the nucleus and bind to DNA to induce NF-κB target gene
transcription. The non-canonical pathway (right) is activated by specific stimuli like B cell activating factor, lymphotoxin β, LIGHT and CD40L. NF-κB
inducing kinase (NIK) is stabilized and activates and recruits IKKα into the p100 complex to phosphorylate p100, leading to p100 ubiquitination.
Processing of p100 generates the p52/RelB NF-κB complex, which is able to translocate to the nucleus and induce gene expression.
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and the importance of the canonical NF-κB pathway in
arthritis is underlined by the beneficial effects of specific
IKKβ inhibition in preclinical models of arthritis [6,7] and
the common and successful use of anti-TNF therapy in
RA, one of the main target genes of the canonical NF-κB
pathway. This is outside the scope of the current review,
however, but is discussed in more detail in previous re-
views [2,3]. Here we focus on the alternative or non-
canonical NF-κB pathway.
The non-canonical NF-κB pathway
In the past decade, a second, alternative NF-κB activa-
tion pathway was identified, the so-called non-canonical
NF-κB pathway (Figure 1). This pathway can be trig-
gered by the activation of members of the TNF-receptor
superfamily including the lymphotoxin β (LTβ) receptor
(LTβR), CD40, B cell activating factor (BAFF) belonging
to the TNF family receptor, and receptor activator of
NF-κB (RANK). Of note, these receptors not only trigger
the non-canonical NF-κB pathway, but simultaneously
also the canonical pathway. The non-canonical NF-κB
pathway is strictly dependent on IKKα homodimers and
unlike the canonical pathway does not involve IKKβ or
IKKγ [8]. In the steady state, NF-κB inducing kinase
(NIK), the most important kinase of the non-canonical
pathway, is continuously degraded. TRAF3 mediates re-
cruitment of NIK to TRAF2, which leads to ubiquitinationof NIK. Consequently, endogenous levels of NIK are very
low and the NF-κB complex is retained in the cytoplasm
and kept inactive. Upon signal-induced activation of the
non-canonical NF-κB pathway, TRAF2 induces proteolysis
of TRAF3. Degradation of TRAF3 prevents targeting of
newly synthesized NIK, resulting in accumulation of NIK.
Subsequently, NIK induces processing of p100 by IKKα
homodimers, resulting in partial degradation into p52.
Next, mainly p52-RelB heterodimers translocate to the
nucleus, leading to target gene transcription. Whereas
canonical NF-κB activation is rapid and independent of
protein synthesis, non-canonical NF-κB activation re-
quires NIK synthesis and accumulation. Consequently,
the kinetics of this pathway are considerable slower
(reviewed in [4,8]).
Of note, ligands of the TNF-receptor superfamily simul-
taneously also activate the canonical pathway and regu-
lated cross-talk between both pathways exists at different
levels. IKKα has, for instance, been described to also have
nuclear functions and serves as a regulator of canonical
NF-κB-dependent gene expression through control of
promoter-associated histone phosphorylation after cyto-
kine exposure [9,10]. In macrophages, however, IKKα
also terminates canonical NF-κB-dependent transcrip-
tion of target genes by accelerating both the turnover of
the NF-κB subunits RelA and c-Rel and their removal
from pro-inflammatory gene promoters [11]. Reciprocally,
canonical NF-κB activity suppresses basal non-canonical
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been shown that, under certain circumstances, other sti-
muli, including TNF, can to some extent also activate
non-canonical NF-κB signaling in specific cell types [13],
and IKKα is critical for interferon-α production induced
by Toll-like receptors 7 and 9 [14]. The functional role of
the non-canonical NF-κB pathway in vivo has been estab-
lished by the identification of phenotypic abnormalities
shared by knockout mice or mutants of specific sig-
naling molecules involved in this pathway. Overall, this
pathway is crucially involved in lymphoid organ deve-
lopment and adaptive immune responses [8]. The role
of non-canonical NF-κB signaling in (synovial) inflam-
mation is addressed below.
Non-canonical NF-κB signaling in rheumatoid
arthritis
In the inflamed RA synovial tissue, all stimuli that are
able to induce non-canonical NF-κB signaling are abun-
dantly present. LTβ plays an essential role in lymphoid
organ development and it has been demonstrated that
this is dependent on LTβR-induced non-canonical NF-
κB activation (reviewed in [15]). In RA synovial tissue,
tertiary lymphoid structures (TLSs) can be formed that
often resemble germinal centers with organized B- and
T-cell clusters. Of note, LTβ is also important in the for-
mation of TLSs in RA synovitis [16]. Signaling through
the LTβR can also be induced by LIGHT and high levels
of LIGHT have been observed in serum, synovial tissue, as
well as in synovial fluid of RA patients [17]. In addition,
LIGHT is upregulated on B cells and monocytes in RA
peripheral blood and synovial fluid [18].
Activation of the non-canonical NF-κB pathway can
also be induced via BAFF/BAFF receptor (BAFF-R) or
CD40L/CD40 triggering. CD40L is highly expressed in
RA synovial tissue [19], and elevated in serum and periph-
eral blood of RA patients [20]. Furthermore, CD40L and
CD40 are highly expressed by T lymphocytes and macro-
phages in the synovial fluid of RA patients [21]. In patients
with RA, elevated serum levels of BAFF have been ob-
served [22], and BAFF/BAFF-R are widely expressed in
RA synovium [23].
Interaction of RANK and RANK ligand (RANKL) has
been extensively studied in RA because of the important
role in osteoclast biology. RANKL is highly expressed in
synovial tissue of RA patients with active disease [24]
and increased levels of soluble RANKL are found both
in serum and synovial fluid from RA patients [25].
Together, these studies suggest that activators of the
non-canonical NF-κB pathway play an important role in
RA synovial inflammation, although direct involvement
of the non-canonical NF-κB pathway is hitherto lacking.
Nik−/− mice and aly/aly mice that are homozygous for a
spontaneous recessive point mutation in the geneencoding NIK both lack lymph nodes and have a
disturbed microarchitecture of the spleen. Furthermore,
these mice have reduced humoral and cell-mediated
immune functions, and are more susceptible to infec-
tions, although they do have mature T and B cells [26,27].
Relb−/− mice develop a complex phenotype, including an
autoimmune-like inflammatory syndrome, myeloid hyper-
plasia, multifocal defects in immune responses, and im-
paired development of lymphoid organs [28-30]. These
studies demonstrate that the non-canonical NF-κB path-
way controls the expression of genes involved in B-cell
function and lymphoid organogenesis, as well as cell prolif-
eration and survival. NIK has also been shown to be critical
for inflammation-induced osteoclastogenesis, as NIK-
deficient mice were largely resistant to arthritis with less
osteoclastogenesis and less bone erosion [31]. Importantly,
the non-canonical NF-κB pathway appears to play different
roles in different cell types. Since many cell types are in-
volved in the pathogenesis of RA, it is very difficult to pre-
dict the net overall contribution of non-canonical NF-κB
signaling to synovial inflammation. Therefore, the role of
the non-canonical NF-κB pathway in the most important
cell types involved in RA synovial inflammation is dis-
cussed below.
Macrophages
Inflamed RA synovial tissue contains many macrophages
that contribute to inflammation, which is substantiated
by our observation that the number of CD68+ synovial
sublining macrophages correlates with clinical improve-
ment independent of therapeutic strategy [32]. However,
macrophages are phenotypically heterogeneous, and are
not only the main producers of proinflammatory cyto-
kines like TNF, IL-1, IL-15, IL-18, IL-23, and IL-27 that
play an important role in the persistence of inflammation,
but also generate inhibitory mediators such as IL-10,
transforming growth factor-β, and soluble TNF receptor
(reviewed in [33]). We and others have demonstrated that
the canonical NF-κB pathway plays an important role in
macrophage production of TNF-α and destructive MMPs
[7]. The non-canonical NF-κB pathway is activated during
human monocyte-macrophage differentiation and the
increase in IKKα may act as a brake preventing hyperacti-
vation of the new macrophages [34]. IKKα accelerates
turnover of the classical NF-κB subunits RelA and c-Rel in
macrophages, and their removal from pro-inflammatory
gene promotors, thereby negatively regulating its own ac-
tivation. Consequently, inactivation of IKKα in mice re-
sulted in enhanced inflammation [11]. These data strongly
suggest that the non-canonical NF-κB pathway plays a
regulatory role in macrophages. In contrast to these fin-
dings, non-canonical NF-κB signaling in macrophages is
critical for production of the chemokine CXCL12, which
is required for cells to migrate toward HMGB1, a
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mune effector cells [35].
The abundant presence of non-canonical NF-κB
ligands in RA synovial tissue is likely to induce signaling
in macrophages as well. LIGHT is expressed in CD68+
macrophages and in vitro stimulation of these cells
with LIGHT induced expression of MMP-9 and pro-
inflammatory cytokines TNF-α, IL-6, and IL-8 [36].
Synovial fluid macrophages express increased levels of
CD40 and produce both IL-12p40, TNF-α and IL-10
after CD40 ligation [37]. However, the contribution of
the non-canonical NF-κB pathway to these LIGHT- and
CD40L-induced processes remains to be tested. In
contrast to other leukocytes, macrophages are more
long-lived cells and also persist at inflammatory lesions
during the resolution of inflammation [38]. Therefore,
the non-canonical NF-κB pathway may play a dual role
in macrophages and can act as both a pro-inflammatory
and an anti-inflammatory pathway.
Dendritic cells
In RA synovial tissue, immature and mature dendritic cell
(DC) subsets can be observed in close association with T
cells and B-cell follicles [39]. These DCs may contribute
to ongoing inflammation through presentation of auto-
antigens or production of pro-inflammatory cytokines.
NF-κB is essential for normal DC differentiation, activa-
tion and survival [40]. CD40 ligation on DCs induces early
production of inflammatory cytokines via the canonical
NF-κB pathway, as well as late expression of the anti-
inflammatory enzyme indoleamine 2,3-dioxygenase via
non-canonical NF-κB signaling, which is able to suppress
T-cell activation and to promote T cells with regulatory
functions [41]. Interestingly, both synovial fluid and syn-
ovial tissues of RA patients contain DCs that express func-
tional indoleamine 2,3-dioxygenase [42], pointing towards
a possible mechanism of tolerance in RA synovial inflam-
mation. These results are consistent with in vivo experi-
ments performed in mice lacking functional NIK that
have decreased numbers of DCs which also have lower ex-
pression of costimulatory molecules and exhibit reduced
antigen presentation. Consequently, these DCs have a de-
creased ability to induce expansion of CD25+CD4+ regula-
tory T cells [43]. At the same time, it was demonstrated
that DCs require non-canonical NF-κB signaling to cross-
prime CD8+ T cells [44]. Furthermore, NIK expression in
mouse DCs is also important for supplying co-stimulatory
signals to CD4+ T cells [45]. In human DCs, however, NIK
was not essential for effective antigen presentation [46].
Taken together, the non-canonical NF-κB pathway regu-
lates both pro-inflammatory and anti-inflammatory pro-
cesses in DCs. The net result is likely to rely heavily on
additional stimuli and the microenvironment in which the
cells are present.B cells and plasma cells
B cells are present in the inflamed RA synovial tissue
and the efficacy of anti-CD20 treatment has confirmed
the pivotal role of B cells in the pathogenesis of RA in pa-
tients [47]. The canonical NF-κB pathway was originally
described in B cells and is crucial for B-cell development,
maintenance, and function (reviewed in [48]). However,
the non-canonical pathway also plays an important role in
B-cell biology. IKKα in B cells is crucial for germinal center
formation, and long-lived immunoglobin titers, but not for
primary antibody production [49]. Importantly, NIK also
regulates BAFF-mediated expression of inducible costimu-
lator ligand, a molecule required for follicular helper T cell
generation [50]. In addition, NIK provides survival signals
in B cells, which is illustrated by the fact that B cell-specific
ablation of TRAF2 and TRAF3 (negative regulators of
NIK) markedly enhanced the survival and proliferation of
B cells [51]. Furthermore, non-canonical NF-κB signaling
also regulates plasma cell generation, proliferation and
survival [52]. In conclusion, the non-canonical pathway
plays an important role in B cells and plasma cells by pro-
moting survival, differentiation and antibody production,
which is likely to contribute to the persistence of inflam-
mation in RA.
T cells
Many T cell subsets can be found in RA synovial tissue,
including Th1, Th17 and regulatory T cells (reviewed in
[53]). The canonical NF-κB pathway is well known for
its role in the activation and differentiation of T cells
[54]. In contrast, the role of the non-canonical NF-κB
pathway in T-cell function is less well studied. It has been
shown that NIK and RelB are essential for T-cell activation
via the T-cell receptor/CD3 pathway [55]. NIK and IKKα
have a T-cell-intrinsic function in the regulation of Th17
cells, a subset of CD4+ effector T cells that produce the IL-
17 family of cytokines, which are intimately involved in
autoimmunity, including in RA [56,57]. The non-canonical
NF-κB pathway is also required for the generation of CD4+
T-follicular helper cells mediating B-cell activation and
antibody responses [50]. In contrast, NIK is essential for
the generation of regulatory T cells that dampen inflamma-
tory responses as well [58].
In summary, the non-canonical NF-κB pathway has dual
roles in T cells; it is not only important in T-cell activation
and the induction of Th17 cells, but is also required for
the generation of regulatory T cells.
Osteoclasts
In RA synovial tissue, osteoclasts that resorb bone are
found at sites adjacent to bone, causing local bone de-
struction [59]. Interestingly, aly/aly mice that lack func-
tional NIK have increased bone mineral density and
bone volume. In addition, these mice and Nik−/− mice
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genesis in vitro and in vivo [60,61]. Also, Nik−/− mice
exhibit significantly less periarticular osteoclastogenesis
and less bone erosion in the serum transfer arthritis model
[31]. Interestingly, overexpression of constitutively active
IKKα or p52 restored osteoclastogenesis in aly/aly cells
[60] and re-introduction of RelB, but not p65, in relb−/−
cells rescued osteoclast formation [62]. Activated osteo-
clasts are responsible for the bone loss associated with
RA. Constitutive activation of NIK drives enhanced osteo-
clastogenesis and bone resorption, both in basal condi-
tions and in response to inflammatory stimuli [63]. In
humans, RANKL expressed by synovial fibroblasts [64] or
T cells [65] effectively induces osteoclastogenesis. Also,
IKKα is required for RANKL-induced osteoclast forma-
tion in vitro [66]. In conclusion, non-canonical NF-κB sig-
naling in osteoclasts unambiguously contributes to bone
destruction in RA, suggesting that this pathway may be an
interesting target in these cells.
Synovial fibroblasts
RA synovial fibroblasts (RASFs) create an abnormal
stromal microenvironment that is thought to be crucial
for the persistence of inflammation, not only because of
its architecture, but also by secreting pro-inflammatory
cytokines or by producing growth factors that stimulate
neovascularization. In addition, it has been demonstrated
that RASFs display certain unique features, such as an in-
vasive, tumor-like behavior that is normally not observed
in fibroblasts (reviewed in [67]). Non-canonical NF-κB
signaling contributes to inflammation in RASFs since NIK
is essential for LTβR activation of NF-κB in these cells
[68]. Also, stromal cells from mice lacking functional NIK
showed decreased levels of adhesion molecules and in-
creased CXCL13 expression. These findings suggest that
NIK activity in stromal cells may play an important role in
regulating the migration of immune cells [69]. Stimulation
of RASFs with LIGHT results in upregulation of adhesion
molecules and MMPs [18]. Also, CD40 ligation of RASFs
induces RANKL expression, resulting in enhanced osteo-
clast formation [64]. Stimulation of RASFs with CD40L
also induces the non-canonical pathway target gene
CXCL12, which may promote angiogenesis and the mi-
gration of T cells, B cells, and monocytes/macrophages
into the inflamed synovium [70].
In summary, non-canonical NF-κB signaling in RASFs
contributes to the pathological behavior of these cells,
leading to persistence of inflammation.
Endothelial cells
Endothelial cells (ECs) play a crucial role in the pathoge-
nesis of RA. First, they express adhesion molecules and
produce chemokines, thereby acting as the site of entry
for immune cells into the synovial tissue. In addition, ECsproliferate and give rise to neovascularization that contrib-
utes to the persistence of inflammation (reviewed in [71]).
In synovial tissue containing TLSs, highly differentiated
ECs, such as high endothelial venules, can also be ob-
served [16]. Consequently, the signaling pathways that
control activation of ECs have been extensively studied
and the canonical NF-κB pathway was demonstrated to
play an important role in the expression of many of the
pro-inflammatory genes [72]. Madge and colleagues [73]
reported that LIGHT and LTα1β2, but not TNF, induce
CXCL12 expression in ECs, which required non-canonical
NF-κB signaling. CXCL12 expression in ECs has been
demonstrated in RA synovial tissue as well [74]. In
addition, CXCL12 colocalized with αvβ3, a marker for
neoangiogenesis, in RA ECs, which would suggest that
CXCL12 may be involved in RA synovial tissue angiogen-
esis [74]. We have observed that CXCL12 is expressed by
NIK+ blood vessels in RA synovial tissue. Subsequently,
we established that non-canonical NF-κB signaling in ECs
stimulates pathological angiogenesis [75]. Recently, it was
demonstrated that EC-specific LTβR signaling is crucial
for lymph node and high endothelial venule formation in
mice, designating ECs as an important player in organiz-
ing lymphoid tissue [76]. Unpublished results from our
group further support these data, as we observed high
numbers of NIK+ ECs in TLSs in RA synovial tissue and
correlated this with the presence of perivascular (pre-) fol-
licular dendritic cells. This suggests that these cells may
be important in the formation of TLSs in chronic inflam-
mation (Noort et al., unpublished observations).
In summary, non-canonical NF-κB signaling in ECs is
likely to contribute to angiogenesis and the influx of im-
mune cells into the inflamed RA synovial tissue, thereby
perpetuating the inflammatory response. Therefore, block-
ing this pathway in ECs is probably beneficial in RA.
Targeting the non-canonical NF-κB pathway in
rheumatoid arthritis
Despite the diverse roles of the non-canonical NF-κB path-
way in different cell types, overall this pathway is likely to
contribute to the persistence of inflammation in RA. As
alluded to earlier, non-canonical NF-κB signaling can be
induced via triggering of various TNF-receptor superfamily
members, such as LTβR, CD40, BAFF-R, and RANK, by
their respective ligands. The important role of these
ligand-receptor pairs in (synovial) inflammation is illus-
trated by the numerous attempts of pharmaceutical
companies to target these pathways. Below, we will dis-
cuss compounds that have been tested in RA patients or
preclinical models of RA (Table 1).
Anti-BAFF/BAFF-R treatment
Belimumab, a fully human IgG1 monoclonal antibody to
BAFF, was tested in RA in a phase II placebo-controlled
Table 1 Biologics targeting ligand-receptor pairs involved in non-canonical nuclear factor-κB signaling in
rheumatoid arthritis
Ligand Receptor Biologic Type of agent Activity of biologic Stage of development
BAFF BAFF-R Belimumab (Benlysta; Human Genome
Sciences/GlaxoSmithKline)
Human BAFF-specific antibody Antagonist Phase II
Tabalumab/LY2127399 Human BAFF-specific antibody Antagonist Phase II
CD40L CD40 BI 655064 Humanized CD40-specific antibody Antagonist Phase I in progress
- LTβR Baminercept Human LTβR-IgG1 fusion protein Antagonist Phase II
LTα LTβR Patecluzimab Humanized LTα-specific antibody Depleting and antagonist Phase II in progress
RANKL RANK Denosumab (Prolia/Xgeva; Amgen) Human RANKL-specific antibody Antagonist Phase II
BAFF, B cell activating factor; BAFF-R, BAFF receptor; CD40L, CD40 ligand; Ig, immunoglobulin; LTα, lymphotoxin-α; LTβR, LTβ receptor; RANK, receptor activator of
nuclear factor-κB; RANKL, RANK ligand.
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in this trial, it was not further tested for RA [77]. However,
belimumab has been proven to have a beneficial clinical
effect in systemic lupus erythematosus (SLE) patients and
is licensed for use in SLE in the United States, Canada,
and Europe. A different anti-BAFF monoclonal antibody,
tabalumab, has also been tested in patients with active
RA. This drug showed modest efficacy [78], but neverthe-
less clinical development in RA was discontinued.
Anti-CD40/CD40L treatment
Clinical trials targeting the CD40/CD40L interaction in
RA are currently ongoing, but so far have not been pub-
lished. However, animal models have demonstrated en-
couraging results. In the collagen-induced arthritis (CIA)
model, treatment with agonistic CD40 antibodies at the
time of CIA induction exacerbates disease [79]. In con-
trast, treatment with anti-CD40L antibodies prior to CIA
induction ameliorated development of disease [80], result-
ing in less synovial inflammation, and less bone erosion
[81]. In humans, two clinical studies investigating the
effects of anti-CD40L treatment have been conducted in
patients with SLE. Both ruplizumab and toralizumab
showed promising clinical and laboratory responses in
some SLE patients. However, one of these studies was
discontinued prematurely because of thromboembolic
events [82]. Since then, new reagents inhibiting CD40L-
mediated events that are less likely to increase the risk
of thromboembolic complications have been developed
and clinical trials in RA patients are in progress.
Anti-LTβ/LTβR treatment
In the collagen-induced arthritis model, treatment with
a LTβR-Ig fusion protein resulted in reductions in the
severity of disease and joint tissue damage [83].
The efficacy and safety of baminercept, a LTβR-IgG1
fusion protein, was evaluated in patients with RA in a
placebo-controlled, phase IIb trial [84]. However, baminer-
cept did not exhibit measurable clinical effects in RA
patients. Pateclizumab, a humanized mouse antibody thatspecifically binds LTα in both the soluble LTα3 homotri-
meric form and the surface-expressed LTα1β2 heterotri-
mer, thereby interfering with binding of LT trimers to
their cognate receptors, was tested for safety and efficacy
in a phase I study. Preliminary beneficial effects were ob-
served in RA patients [85] and a phase II trial to further
test pateclizumab is now in progress.
Anti-RANK/RANKL treatment
In mice, treatment with a neutralizing anti-RANKL mono-
clonal antibody in CIA resulted in amelioration of bone
loss [86]. Phase II clinical trials suggest that denosumab-
mediated inhibition of RANKL in RA patients prevents
bone loss at the site of inflammation, but has no apparent
effect on inflammation [87]. Nevertheless, denosumab
could be used as an adjunctive therapy next to established
(biologic) disease-modifying antirheumatic drugs to pre-
vent structural joint damage in RA.
One has to bear in mind that virtually all stimuli that
activate TNF receptor superfamily members and induce
non-canonical pathway signaling simultaneously also
activate the canonical pathway. Hence, determining
whether the observed therapeutic effects of blocking
these receptor-ligand pairs are mediated via inhibition
of the non-canonical pathway or can also be attributed
to effects on canonical NF-κB signaling is difficult and
requires further investigation.
Future perspectives: direct targeting of intracellular
signaling molecules
Rather than indirect inhibition of non-canonical NF-κB
signaling using the compounds described above, direct
inhibition of NIK or IKKα may be more effective. In RA
synovial inflammation, NIK can be targeted using intra-
articular gene therapy (Noort et al., unpublished, on-
going studies in preclinical models of arthritis) or using
small molecule inhibitors. Since NIK levels in normal
cells are usually low, it is anticipated that therapeutics
designed to limit the amount of NIK will not cause
serious side effects. Consequently, NIK inhibition using
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effective treatment option not only for RA but also for
other chronic inflammatory diseases. Recently, a report
was published in which the discovery, structure-based
design, synthesis, and optimization of several selective
NIK inhibitors are described [88]. So far, only one spe-
cific IKKα inhibitor, BAY32-5915, has been reported
[89]. We expect that preclinical studies will soon answer
the question of whether selective targeting of NIK or
IKKα and consecutive non-canonical NF-κB signaling
may be beneficial in (rheumatoid) arthritis as well. Alter-
natively, in some cell types it may be beneficial to actu-
ally stimulate non-canonical NF-κB activity to obtain a
therapeutic effect. Smac mimetics or inhibitor of apop-
tosis protein antagonists that promote degradation of
cIAP1 and cIAP2 are not only able to induce apoptosis
in cancer cells, but also promote stabilization of NIK
and consequent activation of the non-canonical NF-κB
pathway in resting cells [90,91]. Currently, one of these
smac mimetic compounds, called Birinapant, is undergo-
ing clinical development for the treatment of solid tu-
mors and hematological malignancies [92,93].
Conclusion
The studies reviewed above support the role of the non-
canonical NF-κB pathway as a major participant in in-
flammatory responses in general and the pathogenesis ofDr Jekyll
Dendritic cell
MacTreg
Figure 2 Non-canonical nuclear factor-κB signaling in different cell ty
overview of the role of the non-canonical nuclear factor (NF)-κB pathway in
the left side (Dr Jekyll), cells in which non-canonical NF-κB signaling plays a
in which this pathway plays a dual role, which is largely dependent on the
non-canonical NF-κB signaling is pro-inflammatory. Treg, regulatory T cell.RA in particular. NIK and downstream non-canonical NF-
κB signaling have diverse functions, depending on the cell
types in which this pathway is activated. Roughly, in syn-
ovial fibroblasts, osteoclasts, endothelial cells, and B cells/
plasma cells, non-canonical NF-κB signaling contributes
to the inflammatory process by triggering the secretion of
critical inflammatory mediators and matrix-degrading en-
zymes involved in tissue degradation, whereas in macro-
phages, dendritic cells and T cells this pathway has more
pleiotropic functions and can also play a more regulatory,
anti-inflammatory role (Figure 2). In these cells non-
canonical NF-κB signaling shows clear resemblance with
‘The Strange Case of Dr Jekyll and Mr Hyde’ (Robert Louis
Stevenson): there is a good and an evil side. Further eluci-
dation of the precise function of this pathway in individual
cell types will result in a better understanding of the over-
all contribution of the non-canonical NF-κB pathway to
the complex cellular networks involved in RA synovial
inflammation. This will allow the design of better thera-
peutic strategies for the management of this disease, in-
cluding cell type-specific inhibitors or selective targeting
of inhibitors to certain cell types. For this application,
anti-DEC-205 antibodies may be used to target com-
pounds specifically to DCs or to selectively target ECs,
and (peptide) inhibitors can be coupled to a multimodular
recombinant protein that specifically binds to cytokine-
activated endothelium, which has been demonstrated toMr Hyde





pes in rheumatoid arthritis: Dr Jekyll or Mr Hyde? Schematic
cell types involved in the pathogenesis of rheumatoid arthritis. On
n anti-inflammatory role. In the middle (on the dashed line), cells
microenvironment. On the right side (Mr Hyde), cells in which
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in vivo [94].
Although the non-canonical NF-κB pathway has anti-
inflammatory effects in some cell types, we believe that
in chronic inflammation the positive effects of targeting
the non-canonical NF-κB pathway will surpass the pos-
sible negative effects. We anticipate that the advent of
several selective NIK inhibitors will aid in further estab-
lishing the non-canonical NF-κB pathway as a promising
new therapeutic target, not only in RA, but also in other
immune-mediated inflammatory diseases.
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